HLB Life Science Co.,Ltd. Statistics
Want to see KR:067630 full AI Analyst Report?
HLB Life Science Co.,Ltd. (067630) Stock Statistics & Valuation Metrics
Total Valuation
HLB Life Science Co.,Ltd. has a market cap or net worth of KRW 286.34B. The enterprise value is KRW 547.93B.
- Market Cap
- KRW 286.34B
- Enterprise Value
- KRW 547.93B
Share Statistics
HLB Life Science Co.,Ltd. has 121,917,060 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 121,917,060
- Owned by Insiders
- ―
- Owned by Institutions
- 5.06%
Financial Efficiency
HLB Life Science Co.,Ltd.’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is -4.51%.
- Return on Equity (ROE)
- -0.34
- Return on Assets (ROA)
- -0.21
- Return on Invested Capital (ROIC)
- -4.51%
- Return on Capital Employed (ROCE)
- -0.06
- Revenue Per Employee
- ―
- Profits Per Employee
- ―
- Employee Count
- ―
- Asset Turnover
- 0.10
- Inventory Turnover
- 6.81
Valuation Ratios
The current PE Ratio of HLB Life Science Co.,Ltd. is -32.21. HLB Life Science Co.,Ltd.’s PEG ratio is -0.02.
- PE Ratio
- -32.21
- PS Ratio
- 0.00
- PB Ratio
- 4.61
- Price to FCF
- 0.00
- Price to Operating Cash Flow
- -88.49
- PEG Ratio
- -0.02
Income Statement
In the last 12 months, HLB Life Science Co.,Ltd. had revenue of 45.75B and earned -99.79B in profits. Earnings per share was -818.56.
- Revenue
- 45.75B
- Gross Profit
- -494.41M
- Operating Income
- -21.02B
- Pretax Income
- -100.57B
- Net Income
- -99.79B
- EBITDA
- -83.58B
- Earnings Per Share (EPS)
- -818.56
Cash Flow
In the last 12 months, operating cash flow was -22.93B and capital expenditures -25.94B, giving a free cash flow of -48.88B billion.
- Operating Cash Flow
- -22.93B
- Free Cash Flow
- -48.88B
- Free Cash Flow per Share
- -266.89
Dividends & Yields
HLB Life Science Co.,Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- ―
- Earnings Yield
- -3.11%
Stock Price Statistics
- Beta
- 0.52
- 52-Week Price Change
- -48.58%
- 50-Day Moving Average
- 3198.10
- 200-Day Moving Average
- 3344.47
- Relative Strength Index (RSI)
- 29.92
- Average Volume (3m)
- 562.58K
Important Dates
HLB Life Science Co.,Ltd. upcoming earnings date is Mar 25, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 12, 2026
- Next Earnings Date
- Mar 25, 2027
- Ex-Dividend Date
- ―
Financial Position
HLB Life Science Co.,Ltd. as a current ratio of 0.58, with Debt / Equity ratio of 53.93%
- Current Ratio
- 0.58
- Quick Ratio
- 0.52
- Debt to Market Cap
- 0.11
- Net Debt to EBITDA
- -1.76
- Interest Coverage Ratio
- -1.79
Taxes
In the past 12 months, HLB Life Science Co.,Ltd. has paid -666.74M in taxes.
- Income Tax
- -666.74M
- Effective Tax Rate
- 0.01
Enterprise Valuation
HLB Life Science Co.,Ltd. EV to EBITDA ratio is -1.74, with an EV/FCF ratio of -4.52.
- EV to Sales
- 4.05
- EV to EBITDA
- -1.74
- EV to Free Cash Flow
- -4.52
- EV to Operating Cash Flow
- -9.49
Balance Sheet
HLB Life Science Co.,Ltd. has KRW 13.88B in cash and marketable securities with KRW 160.36B in debt, giving a net cash position of -KRW 146.48B billion.
- Cash & Marketable Securities
- KRW 13.88B
- Total Debt
- KRW 160.36B
- Net Cash
- -KRW 146.48B
- Net Cash Per Share
- -KRW 1,201.47
- Tangible Book Value Per Share
- KRW 2,017.83
Margins
Gross margin is -0.96%, with operating margin of -43.15%, and net profit margin of -117.47%.
- Gross Margin
- -0.96%
- Operating Margin
- -43.15%
- Pretax Margin
- -118.81%
- Net Profit Margin
- -117.47%
- EBITDA Margin
- -232.45%
- EBIT Margin
- -244.20%
Analyst Forecast
The average price target for HLB Life Science Co.,Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -42.14%
- EPS Growth Forecast
- 52.55%
Scores
- Smart Score
- ―
- AI Score
- 44

